Janssen’s JNJ-2113 holds potential to become leading treatment for psoriasis: GlobalData
JNJ-2113, a novel, first-in-class oral interleukin 23 receptor (IL-23R) antagonist peptide in adult patients with…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Janssen Pharmaceuticals
Strides gets USFDA nod for Oxybutynin Chloride Tablets
They are used to treat overactive bladder and urinary conditions
Alembic Pharma gets tentative US FDA nod for generic Rivaroxaban tablets
The tablet is the generic of Janssen Pharmaceuticals's reference listed drug product Xarelto